The role of the endothelium in HPS pathogenesis and potential therapeutic approaches

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Gavrilovskaya, Irina ^a   Gorbunova, Elena ^a   Matthys, Valery ^a   Dalrymple, Nadine ^a   MacKow, Erich ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HANTAVIRUS;

EID: 84873805930     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/467059     Document Type: Review

References (193)

1. Kanerva M., Mustonen J., Vaheri A., Pathogenesis of puumala and other hantavirus infections. Reviews in Medical Virology 1998 8 2 67 86 2-s2.0-0031834432 10.1002/(SICI)1099-1654(199804/06)8:2<67::AID-RMV217>3. 0.CO;2-U (Pubitemid 28288156)
2. Heyman P., Vaheri A., Lundkvist A., Avsic-Zupanc T., Hantavirus infections in Europe: from virus carriers to a major public-health problem. Expert Review of Anti-Infective Therapy 2009 7 2 205 217 2-s2.0-64049101616 10.1586/14787210.7.2.205
3. Lee H. W., Lee R. W., Johnson K. M., Isolation of the etiologic agent of Korean hemorrhagic fever. Journal of Infectious Diseases 1978 137 3 298 308 2-s2.0-0018089671 (Pubitemid 8309146)
4. Chang B., Crowley M., Campen M., Koster F., Hantavirus cardiopulmonary syndrome. Seminars in Respiratory and Critical Care Medicine 2007 28 2 193 200 2-s2.0-34247574313 10.1055/s-2007-976491 (Pubitemid 46676913)
5. Duchin J. S., Koster F. T., Peters C. J., Simpson G. L., Tempest B., Zaki S. R., Ksiazek T. G., Rollin P. E., Nichol S., Umland E. T., Moolenaar R. L., Reef S. E., Nolte K. B., Gallaher M. M., Butler J. C., Breiman R. F., Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The New England Journal of Medicine 1994 330 14 949 955 2-s2.0-0028215049 10.1056/NEJM199404073301401 (Pubitemid 24103592)
6. Koster F., Mackow E., Pathogenesis of the hantavirus pulmonary syndrome. Future Virology 2012 7 1 41 51 2-s2.0-84555218337 10.2217/fvl.11.138
7. Nichol S. T., Spiropoulou C. F., Morzunov S., Rollin P. E., Ksiazek T. G., Feldmann H., Sanchez A., Childs J., Zaki S., Peters C. J., Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 1993 262 5135 914 917 2-s2.0-0027910025 (Pubitemid 24014083)
8. Nolte K. B., Feddersen R. M., Foucar K., Zaki S. R., Koster F. T., Madar D., Merlin T. L., McFeeley P. J., Umland E. T., Zumwalt R. E., Hantavirus pulmonary syndrome in the United States: a pathological description of a disease caused by a new agent. Human Pathology 1995 26 1 110 120 2-s2.0-0028796284
9. Zaki S. R., Greer P. W., Coffield L. M., Goldsmith C. S., Nolte K. B., Foucar K., Feddersen R. M., Zumwalt R. E., Miller G. L., Khan A. S., Rollin P. E., Ksiazek T. G., Nichol S. T., Mahy B. W. J., Peters C. J., Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. American Journal of Pathology 1995 146 3 552 579 2-s2.0-0028954686
10. Lähdevirta J., Enger E., Hunderi O. H., Traavik T., Lee H. W., Hantaan virus is related to hemorrhagic fever with renal syndrome in Norway. The Lancet 1982 2 8298 606 2-s2.0-0020480518
11. Lee H. W., Hemorrhagic fever with renal syndrome (HFRS). History, Hantaan virus and epidemiological features. Scandinavian Journal of Infectious Diseases 1982 14 36 82 85 2-s2.0-0020349849 (Pubitemid 13125860)
12. Yanagihara R., Silverman D. J., Experimental infection of human vascular endothelial cells by pathogenic and nonpathogenic hantaviruses. Archives of Virology 1990 111 3-4 281 286 2-s2.0-0025108236 10.1007/BF01311063 (Pubitemid 20289379)
13. Hjelle B., Torres-Pérez F., Hantaviruses in the Americas and their role as emerging pathogens. Viruses 2010 2 12 2559 2586 2-s2.0-79952153970 10.3390/v2122559
14. Schmaljohn C., Knipe D. M., Howley P. M., Bunyaviridae and their replication. Fields Virology 2001 1 Philadelphia, Pa, USA Lipppincott-Raven 1581 1602
15. Gavrilovskaya I. N., Gorbunova E. E., Mackow E. R., Pathogenic hantaviruses direct the adherence of quiescent platelets to infected endothelial cells. Journal of Virology 2010 84 9 4832 4839 2-s2.0-77950813111 10.1128/JVI.02405-09
16. Gavrilovskaya I. N., Gorbunova E. E., Mackow N. A., Mackow E. R., Hantaviruses direct endothelial cell permeability by sensitizing cells to the vascular permeability factor VEGF, while angiopoietin 1 and sphingosine 1-phosphate inhibit hantavirus-directed permeability. Journal of Virology 2008 82 12 5797 5806 2-s2.0-44949117721 10.1128/JVI.02397-07 (Pubitemid 351822254)
17. Gorbunova E., Gavrilovskaya I. N., Mackow E. R., Pathogenic hantaviruses Andes virus and Hantaan virus induce adherens junction disassembly by directing vascular endothelial cadherin internalization in human endothelial cell. Journal of Virology 2010 84 14 7405 7411 2-s2.0-77953763318 10.1128/JVI.00576-10
18. Gorbunova E. E., Gavrilovskaya I. N., Pepini T., Mackow E. R., VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability. Journal of Virology 2011 85 5 2296 2303 2-s2.0-79551692297 10.1128/JVI.02319-10
19. Hammerbeck C. D., Hooper J. W., T cells are not required for pathogenesis in the Syrian hamster model of hantavirus pulmonary syndrome. Journal of Virology 2011 85 19 9929 9944 2-s2.0-80053939265 10.1128/JVI.05356-11
20. Raymond T., Gorbunova E., Gavrilovskaya I. N., Mackow E. R., Pathogenic hantaviruses bind plexin-semaphorin-integrin domains present at the apex of inactive, bent α v β 3 integrin conformers. Proceedings of the National Academy of Sciences of the United States of America 2005 102 4 1163 1168 2-s2.0-12844253063 10.1073/pnas.0406743102 (Pubitemid 40170743)
21. Shrivastava-Ranjan P., Rollin P. E., Spiropoulou C. F., Andes virus disrupts the endothelial cell barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. Journal of Virology 2010 84 21 11227 11234 2-s2.0-77957940689 10.1128/JVI.01405-10
22. Aird W. C., Endothelium as an organ system. Critical Care Medicine 2004 32 5 S271 279 2-s2.0-2942744464
23. Baumgartner-Parzer S. M., Waldhäusl W. K., The endothelium as a metabolic and endocrine organ: its relation with insulin resistance. Experimental and Clinical Endocrinology and Diabetes 2001 109 2 S166 S179 2-s2.0-0034975217 10.1055/s-2001-18579 (Pubitemid 32577580)
24. Valbuena G., Walker D. H., The endothelium as a target for infections. Annual Review of Pathology 2006 1 171 198 2-s2.0-33645734097 10.1146/annurev.pathol.1.110304.100031
25. Gavard J., Breaking the VE-cadherin bonds. FEBS Letters 2009 583 1 1 6 2-s2.0-57749206415 10.1016/j.febslet.2008.11.032
26. Bates D. O., Harper S. J., Regulation of vascular permeability by vascular endothelial growth factors. Vascular Pharmacology 2002 39 4-5 225 237 2-s2.0-0041842763 10.1016/S1537-1891(03)00011-9 (Pubitemid 37490748)
27. Cines D. B., Pollak E. S., Buck C. A., Loscalzo J., Zimmerman G. A., McEver R. P., Pober J. S., Wick T. M., Konkle B. A., Schwartz B. S., Barnathan E. S., McCrae K. R., Hug B. A., Schmidt A. M., Stern D. M., Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998 91 10 3527 3561 2-s2.0-0032525207 (Pubitemid 28225719)
28. Corada M., Mariotti M., Thurston G., Smith K., Kunkel R., Brockhaus M., Lampugnani M. G., Martin-Padura I., Stoppacciaro A., Ruco L., Mcdonald D. M., Ward P. A., Dejana E., Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proceedings of the National Academy of Sciences of the United States of America 1999 96 17 9815 9820 2-s2.0-13044264471 10.1073/pnas.96.17.9815 (Pubitemid 29398815)
29. Dvorak H. F., Brown L. F., Detmar M., Dvorak A. M., Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. American Journal of Pathology 1995 146 5 1029 1039 2-s2.0-0029004025
30. Gavard J., Gutkind J. S., VEGF Controls endothelial-cell permeability promoting β -arrestin-dependent Endocytosis VE-cadherin. Nature Cell Biology 2006 8 11 1223 1234 2-s2.0-33750529948 10.1038/ncb1486 (Pubitemid 44660587)
31. Hippenstiel S., Krüll M., Ikemann A., Risau W., Clauss M., Suttorp N., VEGF induces hyperpermeability by a direct action on endothelial cells. American Journal of Physiology 1998 274 5 L678 L684 2-s2.0-0031836159
32. Hordijk P. L., Endothelial signaling in leukocyte transmigration. Cell Biochemistry and Biophysics 2003 38 3 305 322 2-s2.0-0346789717 10.1385/CBB:38:3:305 (Pubitemid 41270811)
33. Lampugnani M. G., Orsenigo F., Gagliani M. C., Tacchetti C., Dejana E., Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. Journal of Cell Biology 2006 174 4 593 604 2-s2.0-33747165872 10.1083/jcb.200602080 (Pubitemid 44231870)
34. McVerry B. J., Garcia J. G. N., Endothelial cell barrier regulation by sphingosine 1-phosphate. Journal of Cellular Biochemistry 2004 92 6 1075 1085 2-s2.0-16644394172 10.1002/jcb.20088 (Pubitemid 44264219)
35. Mukhopadhyay D., Tsiokas L., Zhou X. M., Foster D., Brugge J. S., Sukhatme V. P., Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995 375 6532 577 581 2-s2.0-0029068339 10.1038/375577a0
36. Park K. W., Morrison C. M., Sorensen L. K., Jones C. A., Rao Y., Chien C. B., Wu J. Y., Urness L. D., Li D. Y., Robo4 is a vascular-specific receptor that inhibits endothelial migration. Developmental Biology 2003 261 1 251 267 2-s2.0-0042663890 10.1016/S0012-1606(03)00258-6 (Pubitemid 36993830)
37. van Hinsbergh V. W. M., van Nieuw Amerongen G. P., Endothelial hyperpermeability in vascular leakage. Vascular Pharmacology 2002 39 4-5 171 172 2-s2.0-0041342955 10.1016/S1537-1891(03)00006-5 (Pubitemid 37490744)
38. Shimizu Y., Newman W., Tanaka Y., Shaw S., Lymphocyte interactions with endothelial cells. Immunology Today 1992 13 3 106 112 2-s2.0-0026513705
39. Breen E. C., VEGF in biological control. Journal of Cellular Biochemistry 2007 102 6 1358 1367 2-s2.0-36849090838 10.1002/jcb.21579 (Pubitemid 350223939)
40. Berger M. M., Hesse C., Dehnert C., Siedler H., Kleinbongard P., Bardenheuer H. J., Kelm M., Bärtsch P., Haefeli W. E., Hypoxia impairs systemic endothelial function in individuals prone to high-altitude pulmonary edema. American Journal of Respiratory and Critical Care Medicine 2005 172 6 763 767 2-s2.0-24944498766 10.1164/rccm.200504-654OC (Pubitemid 41324233)
41. Coller B. S., Shattil S. J., The GPIIb/IIIa (integrin α IIb β 3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend. Blood 2008 112 8 3011 3025 2-s2.0-54049152026 10.1182/blood-2008-06- 077891
42. Bahram F., Claesson-Welsh L., VEGF-mediated signal transduction in lymphatic endothelial cells. Pathophysiology 2010 17 4 253 261 2-s2.0-77955510391 10.1016/j.pathophys.2009.10.004
43. Brakenhielm E., Substrate matters: reciprocally stimulatory integrin and VEGF signaling in endothelial cells. Circulation Research 2007 101 6 536 538 2-s2.0-34748860359 10.1161/CIRCRESAHA.107.160937 (Pubitemid 351325869)
44. Gélinas D. S., Bernatchez P. N., Rollin S., Bazan N. G., Sirois M. G., Immediate and delayed VEGF-mediated NO synthesis in endothelial cells: role of PI3K, PKC and PLC pathways. British Journal of Pharmacology 2002 137 7 1021 1030 2-s2.0-0036899189 10.1038/sj.bjp.0704956 (Pubitemid 35440742)
45. Lampugnani M. G., Dejana E., The control of endothelial cell functions by adherens junctions. Novartis Foundation Symposium 2007 283 238 241 2-s2.0-40949088574
46. Kobayashi H., Lin P. C., Angiopoietin/Tie2 signaling, tumor angiogenesis and inflammatory diseases. Frontiers in Bioscience 2005 10 666 674 2-s2.0-31944441020
47. Takuwa Y., Takuwa N., Sugimoto N., The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities. Journal of Biochemistry 2002 131 6 767 771 2-s2.0-0036597808 (Pubitemid 34717578)
48. Acevedo L. M., Weis S. M., Cheresh D. A., Robo4 counteracts VEGF signaling. Nature Medicine 2008 14 4 372 373 2-s2.0-41849113058 10.1038/nm0408-372 (Pubitemid 351499382)
49. Beauvais D. M., Ell B. J., McWhorter A. R., Rapraeger A. C., Syndecan-1 regulates α v β 3 and α v β 5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. Journal of Experimental Medicine 2009 206 3 691 705 2-s2.0-63449129028 10.1084/jem.20081278
50. Gavard J., Patel V., Gutkind J. S., Angiopoietin-1 Prevents VEGF-Induced Endothelial Permeability by Sequestering Src through mDia. Developmental Cell 2008 14 1 25 36 2-s2.0-37848998838 10.1016/j.devcel.2007.10.019
51. Lampugnani M. G., Dejana E., Adherens junctions in endothelial cells regulate vessel maintenance and angiogenesis. Thrombosis Research 2007 120 2, supplement S1 S6 2-s2.0-36048942028 10.1016/j.thromres.2007.03.009
52. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., Vestweber D., Corada M., Molendini C., Dejana E., M D. M., Functionally specialized junctions between endothelial cells of lymphatic vessels. Journal of Experimental Medicine 2007 204 10 2349 2362 2-s2.0-34948814992 10.1084/jem.20062596 (Pubitemid 47529321)
53. Saharinen P., Tammela T., Karkkainen M. J., Alitalo K., Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends in Immunology 2004 25 7 387 395 2-s2.0-2942668041 10.1016/j.it.2004.05.003 (Pubitemid 38780956)
54. Schraufnagel D. E., Lung lymphatic anatomy and correlates. Pathophysiology 2010 17 4 337 343 2-s2.0-77955516124 10.1016/j.pathophys.2009. 10.008
55. Esser S., Wolburg K., Wolburg H., Breier G., Kurzchalia T., Risau W., Vascular endothelial growth factor induces endothelial fenestrations in vitro. Journal of Cell Biology 1998 140 4 947 959 2-s2.0-0032559597 10.1083/jcb.140.4.947 (Pubitemid 28141231)
56. Kaner R. J., Ladetto J. V., Singh R., Fukuda N., Matthay M. A., Crystal R. G., Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. American Journal of Respiratory Cell and Molecular Biology 2000 22 6 657 664 2-s2.0-0034086608 (Pubitemid 30400243)
57. Mutlu G. M., Sznajder J. I., Mechanisms of pulmonary edema clearance. American Journal of Physiology 2005 289 5 L685 L695 2-s2.0-27144519899 10.1152/ajplung.00247.2005 (Pubitemid 41504397)
58. Schraufnagel D. E., Agaram N. P., Faruqui A., Jain S., Jain L., Ridge K. M., Sznajder J. I., Pulmonary lymphatics and edema accumulation after brief lung injury. American Journal of Physiology 2003 284 5 L891 L897 2-s2.0-0037405720 (Pubitemid 36459036)
59. Dehler M., Zessin E., Bärtsch P., Mairbäurl H., Hypoxia causes permeability oedema in the constant-pressure perfused rat lung. European Respiratory Journal 2006 27 3 600 606 2-s2.0-33644858320 10.1183/09031936.06. 00061505 (Pubitemid 43372536)
60. Voelkel N. F., High-altitude pulmonary edema. The New England Journal of Medicine 2002 346 21 1606 1607 2-s2.0-0037162096 10.1056/NEJM200205233462102 (Pubitemid 34755667)
61. Breslin J. W., Gaudreault N., Watson K. D., Reynoso R., Yuan S. Y., Wu M. H., Vascular endothelial growth factor-C stimulates the lymphatic pump by a VEGF receptor-3-dependent mechanism. American Journal of Physiology 2007 293 1 H709 H718 2-s2.0-34547092416 10.1152/ajpheart.00102.2007 (Pubitemid 47105133)
62. Gavrilovskaya I. N., Peresleni T., Geimonen E., Mackow E. R., Pathogenic hantaviruses selectively inhibit β 3 integrin directed endothelial cell migration. Archives of Virology 2002 147 10 1913 1931 2-s2.0-0036402322 10.1007/s00705-002-0852-0 (Pubitemid 35218716)
63. Lindgren T., Ahlm C., Mohamed N., Evander M., Ljunggren H.-G., Björkström N. K., Longitudinal analysis of the human T cell response during acute hantavirus infection. Journal of Virology 2011 85 19 10252 10260 2-s2.0-80054002068 10.1128/JVI.05548-11
64. + T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, hantavirus pulmonary syndrome. Journal of Immunology 2004 172 5 3297 3304 2-s2.0-1342323894 (Pubitemid 38263722)
65. Battisti A. J., Chu Y. K., Chipman P. R., Kaufmann B., Jonsson C. B., Rossmann M. G., Structural studies of Hantaan virus. Journal of Virology 2011 85 2 835 841 2-s2.0-78650661414 10.1128/JVI.01847-10
66. Jonsson C. B., Figueiredo L. T. M., Vapalahti O., A global perspective on hantavirus ecology, epidemiology, and disease. Clinical Microbiology Reviews 2010 23 2 412 441 2-s2.0-77950651664 10.1128/CMR.00062-09
67. Plyusnin A., Vapalahti O., Vaheri A., Hantaviruses: genome structure, expression and evolution. Journal of General Virology 1996 77 11 2677 2687 2-s2.0-0029849806 (Pubitemid 26390567)
68. Schmaljohn C., Hjelle B., Hantaviruses: a global disease problem. Emerging Infectious Diseases 1997 3 2 95 104 2-s2.0-0031113395 (Pubitemid 127431667)
69. McElroy A. K., Smith J. M., Hooper J. W., Schmaljohn C. S., Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters. Virology 2004 326 1 130 139 2-s2.0-3242723411 10.1016/j.virol.2004.05.018 (Pubitemid 38943012)
70. Jonsson C. B., Schmaljohn C. S., Replication of hantaviruses. Current Topics in Microbiology and Immunology 2000 256 15 32 2-s2.0-0034536885 (Pubitemid 32016371)
71. Alfadhli A., Love Z., Arvidson B., Seeds J., Willey J., Barklis E., Hantavirus nucleocapsid protein oligomerization. Journal of Virology 2001 75 4 2019 2023 2-s2.0-0035132664 10.1128/JVI.75.4.2019-2023.2001 (Pubitemid 32110195)
72. Pensiero M. N., Hay J., The Hantaan virus M-segment glycoproteins G1 and G2 can be expressed independently. Journal of Virology 1992 66 4 1907 1914 2-s2.0-0026583829
73. Goldsmith C. S., Elliott L. H., Peters C. J., Zaki S. R., Ultrastructural characteristics of Sin Nombre virus, causative agent of hantavirus pulmonary syndrome. Archives of Virology 1995 140 12 2107 2122 2-s2.0-0029444704 10.1007/BF01323234
74. Schmaljohn C. S., Schmaljohn A. L., Dalrymple J. M., Hantaan virus M RNA: coding strategy, nucleotide sequence, and gene order. Virology 1987 157 1 31 39 2-s2.0-0023092796 (Pubitemid 17029979)
75. Pensiero M. N., Jennings G. B., Schmaljohn C. S., Hay J., Expression of the Hantaan virus M genome segment by using a vaccinia virus recombinant. Journal of Virology 1988 62 3 696 702 2-s2.0-0023836515 (Pubitemid 18068623)
76. Gavrilovskaya I. N., Brown E. J., Ginsberg M. H., Mackow E. R., Cellular entry of hantaviruses which cause hemorrhagic fever with renal syndrome is mediated by β 3 integrins. Journal of Virology 1999 73 5 3951 3959 2-s2.0-0032946942 (Pubitemid 29189839)
77. Gavrilovskaya I. N., Shepley M., Shaw R., Ginsberg M. H., Mackow E. R., β 3 integrins mediate the cellular entry of hantaviruses that cause respiratory failure. Proceedings of the National Academy of Sciences of the United States of America 1998 95 12 7074 7079 2-s2.0-0032499532 10.1073/pnas.95.12.7074 (Pubitemid 28278109)
78. Mackow E. R., Gavrilovskaya I. N., Cellular receptors and hantavirus pathogenesis. Current Topics in Microbiology and Immunology 2000 256 91 115 2-s2.0-0034530465 (Pubitemid 32016375)
79. Matthys V. S., Gorbunova E. E., Gavrilovskaya I. N., Mackow E. R., Andes virus recognition of human and syrian hamster β 3 integrins is determined by an L33P substitution in the PSI domain. Journal of Virology 2010 84 1 352 360 2-s2.0-72849150672 10.1128/JVI.01013-09
80. Cosgriff T. M., Lewis R. M., Mechanisms of disease in hemorrhagic fever with renal syndrome. Kidney International 1991 40 35 S72 S79 2-s2.0-0025724969
81. Pensiero M. N., Sharefkin J. B., Dieffenbach C. W., Hay J., Hantaan virus infection of human endothelial cells. Journal of Virology 1992 66 10 5929 5936 2-s2.0-0026731010
82. Sundstrom J. B., McMullan L. K., Spiropoulou C. F., Hooper W. C., Ansari A. A., Peters C. J., Rollin P. E., Hantavirus infection induces the expression of RANTES and IP-10 without causing increased permeability in human lung microvascular endothelial cells. Journal of Virology 2001 75 13 6070 6085 2-s2.0-0034974905 10.1128/JVI.75.13.6070-6085.2001 (Pubitemid 32553138)
83. Elliott L. H., Ksiazek T. G., Rollin P. E., Spiropoulou C. F., Morzunov S., Monroe M., Goldsmith C. S., Humphrey C. D., Zaki S. R., Krebs J. W., Maupin G., Gage K., Childs J. E., Nichol S. T., Peters C. J., Isolation of the causative agent of hantavirus pulmonary syndrome. American Journal of Tropical Medicine and Hygiene 1994 51 1 102 108 2-s2.0-0028106801 (Pubitemid 24266295)
84. Schmaljohn A. L., Li D., Negley D. L., Bressler D. S., Turell M. J., Korch G. W., Ascher S., Ascher S., Schmaljohn C. S., Isolation and initial characterization of a newfound hantavirus from California. Virology 1995 206 2 963 972 2-s2.0-0028861659 10.1006/viro.1995.1019
85. Plyusnin A., Vapalahti O., Lankinen H., Lehvaslaiho H., Apekina N., Myasnikov Y., Kallio-Kokko H., Henttonen H., Lundkvist A., Brummer-Korvenkontio M., Gavrilovskaya I., Vaheri A., Tula virus: a newly detected hantavirus carried by European common voles. Journal of Virology 1994 68 12 7833 7839 2-s2.0-0027937971 (Pubitemid 24362670)
86. Vapalahti O., Lundkvist A., Kukkonen S. K. J., Cheng Y., Gilljam M., Kanerva M., Manni T., Pejcoch M., Niemimaa J., Kaikusalo A., Henttonen H., Vaheri A., Plyusnin A., Isolation and characterization of Tula virus, a distinct serotype in the genus Hantavirus, family Bunyaviridae. Journal of General Virology 1996 77 12 3063 3067 2-s2.0-8044244820 (Pubitemid 27056526)
87. Lee P. W., Amyx H. L., Yanagihara R., Partial characterization of Prospect Hill virus isolated from voles in the United States. Journal of Infectious Diseases 1985 152 4 826 829 2-s2.0-0022385493 (Pubitemid 16215964)
88. Matthys V., Gorbunova E. E., Gavrilovskaya I. N., Pepini T., Mackow E. R., The C-terminal 42 residues of the tula virus Gn protein regulate interferon induction. Journal of Virology 2011 85 10 4752 4760 2-s2.0-79955414003 10.1128/JVI.01945-10
89. Geimonen E., Neff S., Raymond T., Kocer S. S., Gavrilovskaya I. N., Mackow E. R., Pathogenic and nonpathogenic hantaviruses differentially regulate endothelial cell responses. Proceedings of the National Academy of Sciences of the United States of America 2002 99 21 13837 13842 2-s2.0-0037109041 10.1073/pnas.192298899 (Pubitemid 35215467)
90. Alff P. J., Gavrilovskaya I. N., Gorbunova E., Endriss K., Chong Y., Geimonen E., Sen N., Reich N. C., Mackow E. R., The pathogenic NY-1 hantavirus G1 cytoplasmic tail inhibits RIG-1- and TBK-1-directed interferon responses. Journal of Virology 2006 80 24 12430 2-s2.0-33845416056 10.1128/JVI.02162-06 (Pubitemid 44904397)
91. Alff P. J., Sen N., Gorbunova E., Gavrilovskaya I. N., Mackow E. R., The NY-1 hantavirus Gn cytoplasmic tail coprecipitates TRAF3 and inhibits cellular interferon responses by disrupting TBK1-TRAF3 complex formation. Journal of Virology 2008 82 18 9115 9122 2-s2.0-50949085475 10.1128/JVI.00290-08
92. Luo B. H., Karanicolas J., Harmacek L. D., Baker D., Springer T. A., Rationally designed integrin β 3 mutants stabilized in the high affinity conformation. Journal of Biological Chemistry 2009 284 6 3917 3924 2-s2.0-63649083644 10.1074/jbc.M806312200
93. Luo B. H., Takagi J., Springer T. A., Locking the β 3 integrin I-like domain into high and low affinity conformations with disulfides. Journal of Biological Chemistry 2004 279 11 10215 10221 2-s2.0-1642305349 10.1074/jbc.M312732200 (Pubitemid 38372626)
94. Zhu J., Luo B. H., Xiao T., Zhang C., Nishida N., Springer T. A., Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Molecular Cell 2008 32 6 849 861 2-s2.0-57749116060 10.1016/j.molcel.2008.11.018
95. Hynes R. O., Structural biology: changing partners. Science 2003 300 5620 755 756 2-s2.0-0038079490 10.1126/science.1084854 (Pubitemid 36532100)
96. Robinson S. D., Reynolds L. E., Wyder L., Hicklin D. J., Hodivala-Dilke K. M., β 3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 11 2108 2114 2-s2.0-8344265218 10.1161/01.ATV.0000143857.27408. de (Pubitemid 39482438)
97. Weis S. M., Cheresh D. A., alphav Integrins in Angiogenesis and Cancer. Cold Spring Harbor Perspectives in Medicine 1 1 a006478
98. Hodivala-Dilke K. M., McHugh K. P., Tsakiris D. A., Rayburn H., Crowley D., Ullman-Culleré M., Ross F. P., Coller B. S., Teitelbaum S., Hynes R. O., β 3-integrin-deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. Journal of Clinical Investigation 1999 103 2 229 238 2-s2.0-0032590042 (Pubitemid 29053141)
99. Hynes R. O., Bader B. L., Hodivala-Dilke K., Integrins in vascular development. Brazilian Journal of Medical and Biological Research 1999 32 5 501 510 2-s2.0-0033127884 (Pubitemid 129540411)
100. French D. L., Coller B. S., Hematologically important mutations: glanzmann thrombasthenia. Blood Cells, Molecules and Diseases 1997 23 1 39 51 2-s2.0-0030857775 10.1006/bcmd.1997.0117 (Pubitemid 27310956)
101. López N., Padula P., Rossi C., Lázaro M. E., Franze-Fernández M. T., Genetic identification of a new hantavirus causing severe pulmonary syndrome in Argentina. Virology 1996 220 1 223 226 2-s2.0-2542509266 10.1006/viro.1996.0305 (Pubitemid 26202353)
102. Enria D., Padula P., Segura E. L., Pini N., Edelstein A., Posse C. R., Weissenbacher M. C., Hantavirus pulmonary syndrome in Argentina possibility of person to person transmission. Medicina 1996 56 6 709 711 2-s2.0-0030309519 (Pubitemid 127528617)
103. Padula P. J., Edelstein A., Miguel S. D. L., López N. M., Rossi C. M., Rabinovich R. D., Hantavirus pulmonary syndrome outbreak in Argentina: molecular evidence for person-to-person transmission of Andes virus. Virology 1998 241 2 323 330 2-s2.0-0032519398 10.1006/viro.1997.8976 (Pubitemid 28384205)
104. Padula P. J., Sanchez A. J., Edelstein A., Nichol S. T., Complete nucleotide sequence of the M RNA segment of Andes virus and analysis of the variability of the termini of the virus S, M and L RNA segments. Journal of General Virology 2002 83 9 2117 2122 2-s2.0-0036712641 (Pubitemid 34993716)
105. Song J. W., Baek L. J., Gajdusek D. C., Yanagihara R., Gavrilovskaya I., Luft B. J., Mackow E. R., Hjelle B., Isolation of pathogenic hantavirus from white-footed mouse (Peromyscus leucopus). The Lancet 1994 344 8937 1637 2-s2.0-0028126901 (Pubitemid 24365370)
106. Koster F., Foucar K., Hjelle B., Scott A., Chong Y. Y., Larson R., McCabe M., Rapid presumptive diagnosis of hantavirus cardiopulmonary syndrome by peripheral blood smear review. American Journal of Clinical Pathology 2001 116 5 665 672 2-s2.0-0035735571 10.1309/CNWF-DC72-QYMR-M8DA (Pubitemid 34453206)
107. Levis S., Rowe J. E., Morzunov S., Enria D. A., St Jeor S., New hantaviruses causing hantavirus pulmonary syndrome in central Argentina. The Lancet 1997 349 9057 998 999 2-s2.0-0030937701 10.1016/S0140-6736(05)62895-4 (Pubitemid 27149809)
108. Bustamante E. A., Levy H., Simpson S. Q., Pleural fluid characteristics in hantavirus pulmonary syndrome. Chest 1997 112 4 1133 1136 2-s2.0-0030765730 (Pubitemid 27446346)
109. Hallin G. W., Simpson S. Q., Crowell R. E., James D. S., Koster F. T., Mertz G. J., Levy H., Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Critical Care Medicine 1996 24 2 252 258 2-s2.0-0030067420 10.1097/00003246-199602000-00012 (Pubitemid 26065332)
110. Hanaoka M., Droma Y., Naramoto A., Honda T., Kobayashi T., Kubo K., Vascular endothelial growth factor in patients with high-altitude pulmonary edema. Journal of Applied Physiology 2003 94 5 1836 1840 2-s2.0-0037405093 (Pubitemid 36457433)
111. Kaner R. J., Crystal R. G., Compartmentalization of vascular endothelial growth factor to the epithelial surface of the human lung. Molecular Medicine 2001 7 4 240 246 2-s2.0-0035317643 (Pubitemid 33701923)
112. Kaner R. J., Crystal R. G., Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak? High Altitude Medicine and Biology 2004 5 4 399 409 2-s2.0-14644415579 10.1089/ham.2004.5.399 (Pubitemid 40309548)
113. Christou H., Yoshida A., Arthur V., Morita T., Kourembanas S., Increased vascular endothelial growth factor production in the lungs of rats with hypoxia-induced pulmonary hypertension. American Journal of Respiratory Cell and Molecular Biology 1998 18 6 768 776 2-s2.0-0032090254 (Pubitemid 128358423)
114. Breslin J. W., Kurtz K. M., Lymphatic endothelial cells adapt their barrier function in response to changes in shear stress. Lymphatic Research and Biology 2009 7 4 229 237 2-s2.0-77952316102
115. Basu A., Chaturvedi U. C., Vascular endothelium: the battlefield of dengue viruses. FEMS Immunology and Medical Microbiology 2008 53 3 287 299 2-s2.0-48449100077 10.1111/j.1574-695X.2008.00420.x
116. Byzova T. V., Goldman C. K., Pampori N., Thomas K. A., Bett A., Shattil S. J., Plow E. F., A mechanism for modulation of cellular responses to VEGF: activation of the integrins. Molecular Cell 2000 6 4 851 860 2-s2.0-0033636606
117. Dejana E., Orsenigo F., Lampugnani M. G., The role of adherens junctions and VE-cadherin in the control of vascular permeability. Journal of Cell Science 2008 121 13 2115 2122 2-s2.0-48049094159 10.1242/jcs.017897
118. London N. R., Whitehead K. J., Li D. Y., Endogenous endothelial cell signaling systems maintain vascular stability. Angiogenesis 2009 12 2 149 158 2-s2.0-67650764015 10.1007/s10456-009-9130-z
119. Wallez Y., Vilgrain I., Huber P., Angiogenesis: the VE-cadherin switch. Trends in Cardiovascular Medicine 2006 16 2 55 59 2-s2.0-32244434845 10.1016/j.tcm.2005.11.008 (Pubitemid 43214527)
120. Baluk P., Tammela T., Ator E., Lyubynska N., Achen M. G., Hicklin D. J., Jeltsch M., Petrova T. V., Pytowski B., Stacker S. A., Ylä-Herttuala S., Jackson D. G., Alitalo K., M D. M., Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. Journal of Clinical Investigation 2005 115 2 247 257 2-s2.0-20144369085 10.1172/JCI200522037 (Pubitemid 40385467)
121. Olsson A. K., Dimberg A., Kreuger J., Claesson-Welsh L., VEGF receptor signalling-in control of vascular function. Nature Reviews Molecular Cell Biology 2006 7 5 359 371 2-s2.0-33646107369 10.1038/nrm1911
122. Nalbandian R. M., Henry R. L., Platelet endothelial cell interactions. Metabolic maps of structures and actions of prostaglandins, prostacyclin, thromboxane and cyclic AMP. Seminars in Thrombosis and Hemostasis 1978 5 2 87 111 2-s2.0-0018220706 (Pubitemid 9103248)
123. Gomez D., Reich N. C., Stimulation of primary human endothelial cell proliferation by IFN1. Journal of Immunology 2003 170 11 5373 5381 2-s2.0-0037852129 (Pubitemid 36617822)
124. Nawroth R., Poell G., Ranft A., Kloep S., Samulowitz U., Fachinger G., Golding M., Shima D. T., Deutsch U., Vestweber D., VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. EMBO Journal 2002 21 18 4885 4895 2-s2.0-18544390381 10.1093/emboj/cdf497
125. Broermann A., Winderlich M., Block H., Frye M., Rossaint J., Zarbock A., Cagna G., Linnepe R., Schulte D., Nottebaum A. F., Vestweber D., Dissociation of VE-PTP from ve-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo. Journal of Experimental Medicine 2011 208 12 2393 2401 2-s2.0-84855493801 10.1084/jem.20110525
126. Galvagni F., Pennacchini S., Salameh A., Rocchigiani M., Neri F., Orlandini M., Petraglia F., Gotta S., Sardone G. L., Matteucci G., Terstappen G. C., Oliviero S., Endothelial cell adhesion to the extracellular matrix induces c-Src-dependent VEGFR-3 phosphorylation without the activation of the receptor intrinsic kinase activity. Circulation Research 2010 106 12 1839 1848 2-s2.0-77954214925 10.1161/CIRCRESAHA.109.206326
127. Soker S., Miao H. Q., Nomi M., Takashima S., Klagsbrun M., VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. Journal of Cellular Biochemistry 2002 85 2 357 368 2-s2.0-0036009760 10.1002/jcb.10140 (Pubitemid 34274903)
128. Stenmark K. R., Fagan K. A., Frid M. G., Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circulation Research 2006 99 7 675 691 2-s2.0-33749345684 10.1161/01.RES.0000243584.45145.3f (Pubitemid 44498302)
129. Garcia J. G. N., Liu F., Verin A. D., Birukova A., Dechert M. A., Gerthoffer W. T., Bamburg J. R., English D., Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. Journal of Clinical Investigation 2001 108 5 689 701 2-s2.0-0034799675 10.1172/JCI200112450 (Pubitemid 32906197)
130. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z., Vascular endothelial growth factor (VEGF) and its receptors. FASEB Journal 1999 13 1 9 22 2-s2.0-0032907687 (Pubitemid 29038270)
131. Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., Söderberg O., Anisimov A., Kholová I., Pytowski B., Baldwin M., Ylä-Herttuala S., Alitalo K., Kreuger J., Claesson-Welsh L., VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO Journal 2010 29 8 1377 1388 2-s2.0-77951498501 10.1038/emboj.2010.30
132. Dvorak H. F., Discovery of vascular permeability factor (VPF). Experimental Cell Research 2006 312 5 522 526 2-s2.0-33344463349 10.1016/j.yexcr.2005.11.026 (Pubitemid 43290329)
133. Dvorak H. F., Sioussat T. M., Brown L. F., Berse B., Nagy J. A., Sotrel A., Manseau E. J., Van De Water L., Senger D. R., Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. Journal of Experimental Medicine 1991 174 5 1275 1278 2-s2.0-0025953395
134. Holmes K., Roberts O. L., Thomas A. M., Cross M. J., Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cellular Signalling 2007 19 10 2003 2012 2-s2.0-34548443831 10.1016/j.cellsig.2007.05.013 (Pubitemid 47354167)
135. Tang N., Wang L., Esko J., Giordano F. J., Huang Y., Gerber H. P., Ferrara N., Johnson R. S., Loss of HIF-1 α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell 2004 6 5 485 495 2-s2.0-7944224442 10.1016/j.ccr.2004.09.026 (Pubitemid 39469984)
136. Pham I., Uchida T., Planes C., Ware L. B., Kaner R., Matthay M. A., Clerici C., Hypoxia upregulates VEGF expression in alveolar epithelial cells in vitro and in vivo. American Journal of Physiology 2002 283 5 L1133 L1142 2-s2.0-0036838846 (Pubitemid 35204907)
137. Sidel'nikov I. N., Anisimova N. I., The mechanisms of the development of tissue hypoxia and the criteria for its assessment in patients with hemorrhagic fever with renal syndrome. Terapevticheskii Arkhiv 1991 63 11 68 70 2-s2.0-0026283194
138. Hutchings H., Ortega N., Plouët J., Extracellular matrix-bound vascular endothelial growth factor promotes endothelial cell adhesion, migration, and survival through integrin ligation. The FASEB Journal 2003 17 11 1520 1522 2-s2.0-0042704757
139. Borges E., Jan Y., Ruoslahti E., Platelet-derived growth factor receptor β and vascular endothelial growth factor receptor 2 bind to the β 3 integrin through its extracellular domain. Journal of Biological Chemistry 2000 275 51 39867 39873 2-s2.0-0034704174 10.1074/jbc.M007040200 (Pubitemid 32064606)
140. Reynolds L. E., Wyder L., Lively J. C., Taverna D., Robinson S. D., Huang X., Sheppard D., Hynes R. O., Hodivala-Dilke K. M., Enhanced pathological angiogenesis in mice lacking β 3 integrin or β 3 and β 5 integrins. Nature Medicine 2002 8 1 27 34 2-s2.0-0036152857 10.1038/nm0102-27 (Pubitemid 34101725)
141. Soker S., Takashima S., Miao H. Q., Neufeld G., Klagsbrun M., Neuropilin-1 is expressed by endothelial and tumor cells as an isoform- specific receptor for vascular endothelial growth factor. Cell 1998 92 6 735 745 2-s2.0-0032549799 10.1016/S0092-8674(00)81402-6 (Pubitemid 28155313)
142. Wang L., Zeng H., Wang P., Soker S., Mukhopadhyay D., Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. The Journal of Biological Chemistry 2003 278 49 48848 48860 2-s2.0-1542571789
143. Hynes R. O., Hodivala-Dilke K. M., Insights and questions arising from studies of a mouse model of Glanzmann thrombasthenia. Thrombosis and Haemostasis 1999 82 2 481 485 2-s2.0-0032725055
144. Murga M., Fernandez-Capetillo O., Tosato G., Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005 105 5 1992 1999 2-s2.0-14944344614 10.1182/blood-2004-07-2598 (Pubitemid 40731783)
145. Becker P. M., Waltenberger J., Yachechko R., Mirzapoiazova T., Sham J. S. K., Lee C. G., Elias J. A., Verin A. D., Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circulation Research 2005 96 12 1257 1265 2-s2.0-21844449129 10.1161/01.RES.0000171756. 13554.49 (Pubitemid 40962103)
146. Gu C., Limberg B. J., Brian Whitaker G., Perman B., Leahy D. J., Rosenbaum J. S., Ginty D. D., Kolodkin A. L., Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165. Journal of Biological Chemistry 2002 277 20 18069 18076 2-s2.0-0037124068 10.1074/jbc.M201681200 (Pubitemid 34967620)
147. Miao H. Q., Soker S., Feiner L., Alonso J. L., Raper J. A., Klagsbrun M., Neuropilin-1 mediates collapsin-1/semaphorin III inhibition of endothelial cell motility: functional competition of collapsin-1 and vascular endothelial growth factor-165. Journal of Cell Biology 1999 146 1 233 242 2-s2.0-0033549556 10.1083/jcb.146.1.233 (Pubitemid 29349977)
148. Koch A. W., Mathivet T., Larrivée B., Tong R. K., Kowalski J., Pibouin-Fragner L., Bouvrée K., Stawicki S., Nicholes K., Rathore N., Scales S. J., Luis E., del Toro R., Freitas C., Bréant C., Michaud A., Corvol P., Thomas J. L., Wu Y., Peale F., Watts R. J., Tessier-Lavigne M., Bagri A., Eichmann A., Robo4 maintains vessel integrity and inhibits angiogenesis by interacting with UNC5B. Developmental Cell 2011 20 1 33 46 2-s2.0-78651433171 10.1016/j.devcel.2010.12.001
149. Marlow R., Binnewies M., Sorensen L. K., Monica S. D., Strickland P., Camilla Forsberg E., Li D. Y., Hinck L., Vascular Robo4 restricts proangiogenic VEGF signaling in breast. Proceedings of the National Academy of Sciences of the United States of America 2010 107 23 10520 10525 2-s2.0-77953803209 10.1073/pnas.1001896107
150. Weitzman M., Bayley E. B., Naik U. P., Robo4: a guidance receptor that regulates angiogenesis. Cell Adhesion & Migration 2008 2 4 220 222 2-s2.0-65349096738
151. Fujiwara M., Ghazizadeh M., Kawanami O., Potential role of the Slit/Robo signal pathway in angiogenesis. Vascular Medicine 2006 11 2 115 121 2-s2.0-33746438460 10.1191/1358863x06vm658ra (Pubitemid 44122769)
152. Jones C. A., Nishiya N., London N. R., Zhu W., Sorensen L. K., Chan A. C., Lim C. J., Chen H., Zhang Q., Schultz P. G., Hayallah A. M., Thomas K. R., Famulok M., Zhang K., Ginsberg M. H., Li D. Y., Slit2-Robo4 signalling promotes vascular stability by blocking Arf6 activity. Nature Cell Biology 2009 11 11 1325 1331 2-s2.0-70449529782 10.1038/ncb1976
153. Pepini T., Gorbunova E. E., Gavrilovskaya I. N., Mackow J. E., Mackow E. R., Andes virus regulation of cellular microRNAs contributes to hantavirus-induced endothelial cell permeability. Journal of Virology 2010 84 22 11929 11936 2-s2.0-78049511215 10.1128/JVI.01658-10
154. Saharinen P., Petrova T. V., Molecular regulation of lymphangiogenesis. Annals of the New York Academy of Sciences 2004 1014 76 87 2-s2.0-2342495793 10.1196/annals.1294.008 (Pubitemid 38594793)
155. Gavrilovskaya I. N., Gorbunova E. E., Mackow E. R., ANDV infection oflymphatic endothelial cells causes giant cell and enhanced permeability responses that are rapamycin and VEGF-C sensitive. Journal of Virology. In press
156. Lähdevirta J., Clinical features of HFRS in Scandinavia as compared with East Asia. Scandinavian Journal of Infectious Diseases 1982 36 93 95 2-s2.0-0020285054 (Pubitemid 13125864)
157. Khan A. S., Khabbaz R. F., Armstrong L. R., Holman R. C., Bauer S. P., Graber J., Strine T., Miller G., Reef S., Tappero J., Rollin P. E., Nichol S. T., Zaki S. R., Bryan R. T., Chapman L. E., Peters C. J., Ksiazek T. G., Hantavirus pulmonary syndrome: the first 100 US cases. Journal of Infectious Diseases 1996 173 6 1297 1303 2-s2.0-19244362513 (Pubitemid 26286787)
158. Krakauer T., Leduc J. W., Krakauer H., Serum levels of tumor necrosis factor- α interleukin-1, and interleukin-6 in hemorrhagic fever with renal syndrome. Viral Immunology 1995 8 2 75 79 2-s2.0-0029590206 (Pubitemid 26025307)
159. Gavrilovskaya I. N., Gorbunova E. E., Koster F., Mackow E. R., Elevated VEGF levelsin pulmonary edema fluid and pbmcs from patients with acute hantavirus pulmonary syndrome. In press
160. Hooper J. W., Larsen T., Custer D. M., Schmaljohn C. S., A lethal disease model for hantavirus pulmonary syndrome. Virology 2001 289 1 6 14 2-s2.0-0035840798 10.1006/viro.2001.1133 (Pubitemid 33016232)
161. Wahl-Jensen V., Chapman J., Asher L., Fisher R., Zimmerman M., Larsen T., Hooper J. W., Temporal analysis of Andes virus and Sin Nombre virus infections of Syrian hamsters. Journal of Virology 2007 81 14 7449 7462 2-s2.0-34447267216 10.1128/JVI.00238-07 (Pubitemid 47047833)
162. Safronetz D., Zivcec M., LaCasse R., Feldmann F., Rosenke R., Long D., Haddock E., Brining D., Gardner D., Feldmann H., Ebihara H., Pathogenesis and host response in Syrian hamsters following intranasal infection with Andes virus. PLoS Pathogens 2011 7 12 e1002426 2-s2.0-84855265604 10.1371/journal. ppat.1002426
163. Jonsson C. B., Hooper J., Mertz G., Treatment of hantavirus pulmonary syndrome. Antiviral Research 2008 78 1 162 169 2-s2.0-40749139151 10.1016/j.antiviral.2007.10.012
164. Jones C. A., London N. R., Chen H., Park K. W., Sauvaget D., Stockton R. A., Wythe J. D., Suh W., Larrieu-Lahargue F., Mukouyama Y. S., Lindblom P., Seth P., Frias A., Nishiya N., Ginsberg M. H., Gerhardt H., Zhang K., Li D. Y., Robo4 stabilizes the vascular network by inhibiting pathologic angiogenesis and endothelial hyperpermeability. Nature Medicine 2008 14 4 448 453 2-s2.0-41849131420 10.1038/nm1742 (Pubitemid 351499393)
165. Wallez Y., Cand F., Cruzalegui F., Wernstedt C., Souchelnytskyi S., Vilgrain I., Huber P., Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site. Oncogene 2007 26 7 1067 1077 2-s2.0-33847050140 10.1038/sj.onc.1209855
166. Wang Y., Jin G., Miao H., Li J. Y. S., Usami S., Chien S., Integrins regulate VE-cadherin and catenins: dependence of this regulation on Src, but not on Ras. Proceedings of the National Academy of Sciences of the United States of America 2006 103 6 1774 1779 2-s2.0-32444440870 10.1073/pnas.0510774103 (Pubitemid 43228769)
167. Huber S., Bruns C. J., Schmid G., Hermann P. C., Conrad C., Niess H., Huss R., Graeb C., Jauch K. W., Heeschen C., Guba M., Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney International 2007 71 8 771 777 2-s2.0-34247279338 10.1038/sj.ki.5002112 (Pubitemid 46624022)
168. Kim D. D., Kleinman D. M., Kanetaka T., Gerritsen M. E., Nivaggioli T., Weber D., Durán W. N., Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation 2010 17 2 128 136 2-s2.0-77953642138 10.1111/j.1549-8719.2009.00012.x
169. Land S. C., Tee A. R., Hypoxia-inducible factor 1 α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. Journal of Biological Chemistry 2007 282 28 20534 20543 2-s2.0-34547134517 10.1074/jbc.M611782200 (Pubitemid 47100043)
170. Phung T. L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R. A., Shiojima I., Nagy J. A., Lin M. I., Walsh K., Dvorak A. M., Briscoe D. M., Neeman M., Sessa W. C., Dvorak H. F., Benjamin L. E., Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 2006 10 2 159 170 2-s2.0-33746800144 10.1016/j.ccr.2006.07.003 (Pubitemid 44175906)
171. Xue Q., Nagy J. A., Manseau E. J., Phung T. L., Dvorak H. F., Benjamin L. E., Rapamycin Inhibition of the Akt/mTOR Pathway Blocks Select Stages of VEGF-A164-Driven Angiogenesis, in Part by Blocking S6Kinase. Arteriosclerosis, Thrombosis, and Vascular Biology 2009 29 8 1172 1178 2-s2.0-68149169793 10.1161/ATVBAHA.109.185918
172. Teijaro J. R., Walsh K. B., Cahalan S., Fremgen D. M., Roberts E., Scott F., Martinborough E., Peach R., Oldstone M. B. A., Rosen H., Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011 146 6 980 991 2-s2.0-80052940381 10.1016/j.cell.2011.08.015
173. Schmid G., Guba M., Ischenko I., Papyan A., Joka M., Schrepfer S., Bruns C. J., Jauch K. W., Heeschen C., Graeb C., The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1. Journal of Cellular Biochemistry 2007 101 1 259 270 2-s2.0-34147095398 10.1002/jcb.21181 (Pubitemid 46652589)
174. Porkka K., Khoury H. J., Paquette R. L., Matloub Y., Sinha R., Cortes J. E., Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010 116 2 377 386 2-s2.0-75649105405 10.1002/cncr.24734
175. Acevedo L. M., Barillas S., Weis S. M., Göthert J. R., Cheresh D. A., Semaphorin 3A suppresses VEGF-mediated angiogenesis yet acts as a vascular permeability factor. Blood 2008 111 5 2674 2680 2-s2.0-41949129114 10.1182/blood-2007-08-110205
176. Xu D., Fuster M. M., Lawrence R., Esko J. D., Heparan sulfate regulates VEGF165- and VEGF121- mediated vascular hyperpermeability. Journal of Biological Chemistry 2011 286 1 737 745 2-s2.0-78650939979 10.1074/jbc.M110.177006
177. Brinkmann V., Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacology and Therapeutics 2007 115 1 84 105 2-s2.0-34250832664 10.1016/j.pharmthera.2007.04.006 (Pubitemid 46990553)
178. Peng X., Hassoun P. M., Sammani S., McVerry B. J., Burne M. J., Rabb H., Pearse D., Tuder R. M., Garcia J. G. N., Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. American Journal of Respiratory and Critical Care Medicine 2004 169 11 1245 1251 2-s2.0-2542461296 (Pubitemid 38680403)
179. Sanchez T., Estrada-Hernandez T., Paik J. H., Wu M. T., Venkataraman K., Brinkmann V., Claffey K., Hla T., Phosphosrylation and action of the immunomodulator FTY720 inhibits 'vascular endothelial cell growth factor-induced vascular permeability. Journal of Biological Chemistry 2003 278 47 47281 47290 2-s2.0-0344443651 10.1074/jbc.M306896200 (Pubitemid 37452317)
180. Jain R. K., Munn L. L., Leaky vessels? Call ang1! Nature Medicine 2000 6 2 131 132 2-s2.0-17544385146 10.1038/72212 (Pubitemid 30082345)
181. Pizurki L., Zhou Z., Glynos K., Roussos C., Papapetropoulos A., Angiopoietin-1 inhibits endothelial permeability, neutrophil adherence and IL-8 production. British Journal of Pharmacology 2003 139 2 329 336 2-s2.0-0037592684 10.1038/sj.bjp.0705259 (Pubitemid 36760365)
182. Satchell S. C., Anderson K. L., Mathieson P. W., Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. Journal of the American Society of Nephrology 2004 15 3 566 574 2-s2.0-1542349097 10.1097/01.ASN.0000115397.22519.03 (Pubitemid 38294786)
183. Thurston G., Suri C., Smith K., McClain J., Sato T. N., Yancopoulos G. D., McDonald D. M., Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999 286 5449 2511 2514 2-s2.0-0033601357 10.1126/science.286.5449.2511 (Pubitemid 30026340)
184. McVerry B. J., Garcia J. G. N., In vitro and in vivo modulation of vascular barrier integrity by sphingosine 1-phosphate: mechanistic insights. Cellular Signalling 2005 17 2 131 139 2-s2.0-5644287793 10.1016/j.cellsig.2004. 08.006 (Pubitemid 39371042)
185. Podar K., Tonon G., Sattler M., Tai Y. T., LeGouill S., Yasui H., Ishitsuka K., Kumar S., Kumar R., Pandite L. N., Hideshima T., Chauhan D., Anderson K. C., The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proceedings of the National Academy of Sciences of the United States of America 2006 103 51 19478 19483 2-s2.0-33845882259 10.1073/pnas.0609329103 (Pubitemid 46026056)
186. McVerry B. J., Peng X., Hassoun P. M., Sammani S., Simon B. A., Garcia J. G. N., Sphingosine 1-phosphate reduces vascular leak in murine and canine models of acute lung injury. American Journal of Respiratory and Critical Care Medicine 2004 170 9 987 993 2-s2.0-7044241285 10.1164/rccm.200405-684OC (Pubitemid 39425695)
187. Morgan M. R., Humphries M. J., Bass M. D., Synergistic control of cell adhesion by integrins and syndecans. Nature Reviews Molecular Cell Biology 2007 8 12 957 969 2-s2.0-36448970493 10.1038/nrm2289 (Pubitemid 350174639)
188. Beauvais D. M., Rapraeger A. C., Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. Journal of Cell Science 2010 123 21 3796 3807 2-s2.0-78149325327 10.1242/jcs.067645
189. Schuksz M., Fuster M. M., Brown J. R., Crawford B. E., Ditto D. P., Lawrence R., Glass C. A., Wang L., Tor Y., Esko J. D., Surfen, a small molecule antagonist of heparan sulfate. Proceedings of the National Academy of Sciences of the United States of America 2008 105 35 13075 13080 2-s2.0-51349149624 10.1073/pnas.0805862105
190. Albig A. R., Schiemann W. P., Fibulin-5 antagonizes vascular endothelial growth factor (VEGF) signaling and angiogenic sprouting by endothelial cells. DNA and Cell Biology 2004 23 6 367 379 2-s2.0-3042742348 10.1089/ 104454904323145254 (Pubitemid 38850384)
191. Freeman L. J., Lomas A., Hodson N., Sherratt M. J., Mellody K. T., Weiss A. S., Shuttleworth A., Kielty C. M., Accelerated publication fibulin-5 interacts with fibrillin-1 molecules and microfibrils. Biochemical Journal 2005 388 1 1 5 2-s2.0-19544386091 10.1042/BJ20050368 (Pubitemid 40732926)
192. Guadall A., Orriols M., Rodríguez-Calvo R., Calvayrac O., Crespo J., Aledo R., Martínez-González J., Rodríguez C., Fibulin-5 is up-regulated by hypoxia in endothelial cells through a hypoxia-inducible factor-1 (HIF-1 α)-dependent mechanism. Journal of Biological Chemistry 2011 286 9 7093 7103 2-s2.0-79953253003 10.1074/jbc.M110.162917
193. Otrock Z. K., Makarem J. A., Shamseddine A. I., Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells, Molecules, and Diseases 2007 38 3 258 268 2-s2.0-34047141776 10.1016/j.bcmd.2006.12.003 (Pubitemid 46518176)